|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | High-intensity focused ultrasound ablation:An effective bridging therapy for hepatocellular carcinoma patients显示文摘AIM:To analyze whether high-intensity focused ultrasound(HIFU) ablation is an effective bridging therapy for patients with hepatocellular carcinoma(HCC).METHODS:From January 2007 to December 2010,49 consecutive HCC patients were listed for liver transplantation(UCSF criteria).The median waiting time for transplantation was 9.5 mo.Twenty-nine patients received transarterial chemoembolization(TACE) as a bringing therapy and 16 patients received no treatment before transplantation.Five patients received HIFU ablation as a bridging therapy.Another five patients with the same tumor staging(within the UCSF criteria) who received HIFU ablation but not on the transplant list were included for comparison.Patients were comparable in terms of Child-Pugh and model for end-stage liver disease scores,tumor size and number,and cause of cirrhosis.RESULTS:The HIFU group and TACE group showed no difference in terms of tumor size and tumor number.One patient in the HIFU group and no patient in the TACE group had gross ascites.The median hospital stay was 1 d(range,1-21 d) in the TACE group and two days(range,1-9 d) in the HIFU group(P < 0.000).No HIFU-related complication occurred.In the HIFU group,nine patients(90%) had complete response and one patient(10%) had partial response to the treatment.In the TACE group,only one patient(3%) had response to the treatment while 14 patients(48%) had stable disease and 14 patients(48%) had progressive disease(P = 0.00).Seven patients in the TACE group and no patient in the HIFU group dropped out from the transplant waiting list(P = 0.559).CONCLUSION:HIFU ablation is safe and effective in the treatment of HCC for patients with advanced cirrhosis.It may reduce the drop-out rate of liver transplant candidate. | Tan To Cheung Sheung Tat Fan See Ching Chan Kenneth SH Chok Ferdinand SK Chu Caroline R Jenkins Regina CL Lo James YY Fung Albert CY Chan William W Sharr Simon HY Tsang Wing Chiu Dai Ronnie TP Poon Chung Mau Lo | 2013 | World Journal of Gastroenterology2013，19，20： | 23 |
| 2 | Prevention of recurrent hepatitis B infection after liver transplantation显示文摘BACKGROUND:Recurrence of hepatitis B virus(HBV) infection after liver transplantation can lead to graft loss and a reduction in long-term survival.The purpose of this review is to summarize the current therapeutic options for preventing HBV recurrence in liver transplant recipients.DATA SOURCES:Up to January 2013,studies that were published in MEDLINE and EMBASE on prevention of HBV recurrence after liver transplantation were reviewed.RESULTS:There have been remarkable advancements in the past two decades on the prevention of HBV recurrence after liver transplantation,from the discovery of hepatitis B immune globulin(HBIG) and lamivudine monotherapy to the combination therapy using HBIG and lamivudine.With the development of newer and stronger antiviral agents,the need for life-long HBIG is doubtful.With their low resistance profile,oral antiviral prophylaxis using these new agents alone is sufficient and is associated with excellent outcome.CONCLUSIONS:Restoration of host HBV immunity with adoptive immunity transfer and vaccination may represent the ultimate strategy to withdraw prophylactic treatment and to achieve a drug free regimen against HBV recurrence after liver transplantation. | Tiffany CL Wong James YY Fung Chung Mau Lo | 2013 | Hepatobiliary & Pancreatic Diseases International2013，12，5： | 5 |
| 3 | Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B显示文摘 | Fung J Lai CL Seto WK | 2011 | J Antimicrob Chemother2011，66，12： | 1 |
| 4 | Fascin expression predicts survival after potentially curative resection of node-positive colon cancer显示文摘 | Chan C Jankova L Fung CL | | 0，，： | 1 |
| 5 | Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome 显示文摘 | Seto WK Lai CL Fung J | 2011 | J Hepatol2011，55，3： | 1 |
| 6 | Caleineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology显示文摘 | NankivellBJ Borrows RJ Fung CL | 2004 | Transplantation2004，78，4： | 1 |
| 7 | The natural history of chronic allogralt nephropathy显示文摘 | Nanldvell BJ Borrows RJ Fung CL et ol | 2003 | N Eng J Meal2003，349，24： | 1 |
| 8 | Evolution and pathophys-iology of renal-transplant glomerulosclerosis显示文摘 | Nankivell BJ Borrows RJ Fung CL | 2004 | Transplantation2004，，78： | 1 |
| 9 | Profile of HBV DNA in a large population of Chinese patients with chronic hepatitis B:implications for antiviral therapy显示文摘 | Fung J Seto WK Lai CL | 2011 | J Hepatol2011，54，2： | 1 |
| 10 | Significant changes in liver stiffness measurements in patients with chronic hepati tis B: 3 year follow-up study 显示文摘 | Fung J Lai CL Wong DK etal | 2011 | J Viral Hepatol2011，18，7： | 1 |
| 11 | Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology显示文摘 | Nankivell BJ Borrows RJ Fung CL | 2004 | Transplantation2004，78，4： | 1 |
| 12 | Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B 显示文摘 | Fung J Lai CL Yuen MF | 2010 | Expert rev anti infect ther2010，8，6： | 1 |
| 13 | Hepatitis B and C virus-related carcinogenesis显示文摘 | Fung J Lai CL Yuen MF | 2009 | Clin Microbiol Infect2009，15，11： | 1 |
| 14 | Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis显示文摘 | Fung J Lai CL Fong DY | 2008 | Liver Int2008，28，10： | 1 |
| 15 | The natural history of chronic allograft nephropathy显示文摘 | Nankivell BJ Borrows RJ Fung CL | 2003 | N Engl J Med2003，349，24： | 1 |
| 16 | The natural history of chronic allograft nephropathy显示文摘 | NANKIVELL B J BORROWS RJ FUNG CL | 2003 | N Engl J Med2003，349，24： | 1 |
| 17 | Natural history of chronic hepatitis C: genotype 1 versus genotype 6显示文摘 | Seto WK Lai CL Fung J | 2010 | J Hepatol2010，53，3： | 1 |
| 18 | The natural history of chronic allograft nephropathy显示文摘 | NANKIVELL B J BORROWS R J FUNG CL | 2003 | N Engl J Med2003，349，24： | 1 |
| 19 | Hepatitis B virus DNA and hepatitis B sur-face antigen levels in chronic hepatitis B显示文摘 | Fung J Lai CL Yuen MF | 2010 | Expert Rev Anti Infect Ther2010，248，： | 1 |
| 20 | One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels显示文摘 | Wong DK Yuen MF Ngai VW Fung J Lai CL | | Antiviral Therapy0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员